NCT00792012View on ClinicalTrials.gov

A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Glioblastoma Multiforme
Interventions
RADIATION

Hypofractionated Intensity-Modulated Radiation Therapy

All patients will receive one fraction of radiation therapy a day, 5 days a week, Monday through Friday. Radiation fraction size and number of fractions depend on dose fraction level the patient is assigned to.

DRUG

Temozolomide

Temozolomide will be administered orally, once a day starting on the first day of radiation, for 28 consecutive days during radiation, and after radiation for those patients completing radiation in less than 28 days.

Trial Locations (1)

80045

University of Colorado Cancer Center, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER

NCT00792012 - A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma | Biotech Hunter | Biotech Hunter